Eledon Pharmaceuticals, Inc.
ELDN
NASDAQ·Healthcare·Biotechnology·Mkt cap $233.1M
$3.02
▲ +3.07%
P/E
—
Mkt Cap
$233.1M
52-Wk Range
$1.35–$4.60
52-Week Range
$1.35 - $4.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 17.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CD40 Ligand targeting technology with differentiated mechanism of action
- Dual clinical development pathway maximizing market opportunity and revenue potential
- Specialized expertise in transplant immunology addressing underserved patient populations
- Humanized monoclonal antibody platform enabling reduced immunogenicity and improved tolerability
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of AT-1501 through Phase 2 clinical trials with potential for accelerated approval pathways
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-15.6% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying ELDN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 13, 2026
Reported EPS of -$0.27 vs -$0.16 consensus (-70.9% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-70.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Rodman & Renshaw · Jul 21, 2026
vs Industry
How ELDN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related